GET HELP NOW

Monday, March 12, 2018

Canakinumab reduces risk of cardiovascular events in populations with unmet clinical need

http://ift.tt/eA8V8J Two new analyses of data from more than 10,000 heart attack survivors worldwide were presented at a recent meeting. Scientists assessed whether the anti-inflammatory therapy canakinumab reduced rates of major adverse cardiovascular events and co-morbidities among high-risk atherosclerotic patients with chronic kidney disease (CKD) or those with pre-diabetes/diagnosed type 2 diabetes, respectively.

from http://ift.tt/2tFFY64
via IFTTT
at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Children whose mothers use marijuana are more likely to try it at younger age

When mothers use marijuana during the first 12 years of their child's life, their cannabis-using children are more likely to start at an...